title: Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia.
abstract: Lymphoblasts from 93 children with acute lymphoblastic leukemia (ALL) were characterized by immunologic cell surface markers. These patients were treated on a single protocol, featuring adriamycin therapy during remission, and have been followed from 2 to 6.5 yr (median 4 yr). Three classes of patients were defined serologically: HTA+ Ia- CALLA-, Ia+ CALLA+ HTA-, and Ia+ CALLA- HTA-. Disease-free survival and sites of relapse were assessed within immunologic subsets. Similar to the findings of others, T-cell (HTA+ Ia-) patients fared poorly as compared to non-T-cell (Ia+ HTA-) patients (median disease-free survival was 12 and 47 mo. respectively; p = 0.0004). The majority of relapses in the HTA+ patients occurred at extramedullary sites. Late testicular relapse was rare among Ia+ patients. In addition, the "common ALL antigen" (CALLA) may identify a relatively favorable subset within the Ia+ population. The prognostic value of the immunologic markers was compared with traditional clinical factors. There was much overlap between HTA+, older age, and elevated WBC. However, neither age nor WBC alone were of prognostic significance among the Ia+ patients. We conclude that surface markers define both biologic and prognostic characteristics. The course of childhood ALL must be viewed in the context of homogeneous subsets and within particular therapeutic programs.
mesh_terms: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D005260:Female; D005455:Fluorescent Antibody Technique; D006649:Histocompatibility Antigens; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D008297:Male; D011379:Prognosis; D012075:Remission, Spontaneous
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D006649:Histocompatibility Antigens; D007106:Immune Sera